FDA tentatively approves generic AIDS drug

Share this article:
The FDA granted tentative approval to the generic drug lamivudine for pediatric patients with HIV.
As such, lamivudine will be available for purchase outside the U.S. under President Bush's Emergency Plan for AIDS Relief, a $15-billion plan to provide treatment and palliative care to patients with HIV/AIDS over five years and prevent new cases among 15 of the hardest hit countries.
The drug will be manufactured by Hyderabad, India concern Aurobindo Pharma LTD.
The FDA action marks the first generic version of Epivir Oral Solution, manufactured by GlaxoSmithKline. If the generic were to gain full approval, it would become the second non-branded AIDS treatment.
Another generic antiretroviral drug product, didanosine from Barr Laboratories, has full approval for U.S marketing.
The agency said its tentative approval means that, although existing patents and/or exclusivity prevent U.S. marketing of the drug, lamivudine meets FDA safety, efficacy, and manufacturing quality standards required for sales in the U.S.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...